Title: 68Ga-DOTA-Substance-P as a Tool for Diagnostics and Locoregional Administration Follow up of 213Bi-DOTA-Substance-P in the Course of Glioma Therapy
Authors: PAWLAK DariuszGARNUSZEK PiotrMAURIN MichalKROLICKI LeszekKUNIKOWSKA JolantaMORGENSTERN AlfredBRUCHERTSEIFER FrankJAKUCINSKI MKOZIARA HKROLICKI BMIKOLAJCZAK Renata
Citation: World Journal of Nuclear Medicine vol. 12 no. Supplement 1 p. 52-53 (Paper n° O-020)
Publisher: Medknow
Publication Year: 2013
JRC N°: JRC80891
ISSN: 1450-1147 (print), 1607-3312 (online)
URI: www.wjnm.org
http://publications.jrc.ec.europa.eu/repository/handle/JRC80891
Type: Articles in periodicals and books
Abstract: Gliomas, world Health Organization (WHO) grade II-IV, have been shown to consistently overexpress the transmembrane neurokinin type I receptor (NK-1). NK-1 receptors have also been detected in tumor cells inltrating the intra- and peritumoral vasculature. Peptide Substance P is a physiological ligand for NK-1 receptor and can be labeled with various radionuclides using chelators suitable for e.g., 68Ga and 213Bi. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8, Met (O2)11]-substance-P has been reported. In this work, 111In-DOTA-[Thi8, Met (O2)11]-substance-P was used for evaluation of receptor expression and dose distribution (Single-photon emission computed tomography (SPECT) and low-dose computed tomography (CT)). The aim of our work was to perform Positron emission tomography (PET) imaging using 68Ga-DOTA-[Thi8, Met (O2)11]-substance-P co-injected with 213Bi-DOTA-[Thi8, Met (O2)11]-substance-P therapeutic dose administered to the glioma patient via catheter directly to the cavity after tumor resection in order to assess the post-therapeutic dose distribution.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.